- Roth Capital is out with some positive commentary on Synta Pharmaceuticals (SNTA +10.5%) following the announcement of new clinical trials for ganetespib.
- "We continue to look towards interim analysis from the GALAXY-2 trial in NSCLC in H2 and top-line data in H1 2015," analyst Joseph Pantginis says, adding that "as the ganetespib profile continues to broaden, [he] continues to believe that the drug is ripe for a partnership in the relative near term."
- Price target is $27, representing upside of 295% from Thursday's close.
From other sites
at Zacks.com (Mar 12, 2015)
at Zacks.com (Mar 11, 2015)
at Zacks.com (Mar 6, 2015)
at CNBC.com (Jan 10, 2014)
at CNBC.com (Oct 16, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs